益生股份(002458.SZ):10月雞苗銷售收入同增191.23% 環增30.77%
格隆匯11月4日丨益生股份(002458.SZ)公佈,公司2019年10月雞苗銷售數量3859.51萬隻,銷售收入4.48億元,同比變動分別為52.36%、191.23%,環比變動分別為10.22%、30.77%。
2019年10月,公司雞苗銷售數量、銷售收入環比、同比上升,主要原因是:
1、公司父母代種雞的存欄量增加,再加上併購煙台益春種禽有限公司,產能釋放,雞苗銷售數量大幅上漲。
2、受雞肉供給緊張和需求替代影響,行業景氣度高,公司主營產品父母代肉種雞雛雞及商品代肉雛雞價格較去年同期大幅上漲。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.